Citi resumed coverage of Merck (MRK) with a Neutral rating and price target of $95, up from $84. The firm sees the company’s Keytruda Qlex, Winrevair and pipeline opportunities being the focus for investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
- Merck & Company: Undervalued with Promising Growth Prospects Despite Near-Term Challenges
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan